JP2009544734A - 目の障害の予防および処置のための内皮分化遺伝子ファミリー3(edg−3、s1p3)レセプターのアンタゴニスト - Google Patents
目の障害の予防および処置のための内皮分化遺伝子ファミリー3(edg−3、s1p3)レセプターのアンタゴニスト Download PDFInfo
- Publication number
- JP2009544734A JP2009544734A JP2009521989A JP2009521989A JP2009544734A JP 2009544734 A JP2009544734 A JP 2009544734A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009544734 A JP2009544734 A JP 2009544734A
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- alkyl
- receptor
- eye
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 73
- 102000005962 receptors Human genes 0.000 title claims abstract description 33
- 108020003175 receptors Proteins 0.000 title claims abstract description 33
- 208000030533 eye disease Diseases 0.000 title claims abstract description 24
- 102000036530 EDG receptors Human genes 0.000 title claims description 16
- 108091007263 EDG receptors Proteins 0.000 title claims description 16
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 title abstract description 13
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 title abstract description 10
- 238000011282 treatment Methods 0.000 title description 6
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 title description 4
- 230000002265 prevention Effects 0.000 title description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims abstract description 37
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 26
- 230000011664 signaling Effects 0.000 claims abstract description 26
- 238000009825 accumulation Methods 0.000 claims abstract description 21
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 19
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 11
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims abstract description 10
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims abstract description 10
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims abstract description 10
- 206010038934 Retinopathy proliferative Diseases 0.000 claims abstract description 10
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims abstract description 10
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims abstract description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000029663 wound healing Effects 0.000 claims abstract description 8
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 7
- 206010038923 Retinopathy Diseases 0.000 claims abstract description 7
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 201000001119 neuropathy Diseases 0.000 claims abstract description 6
- 230000007823 neuropathy Effects 0.000 claims abstract description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 55
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 28
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate group Chemical group P(=O)(O)(O)OC[C@H](N)[C@H](O)\C=C\CCCCCCCCCCCCC DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 9
- 150000003548 thiazolidines Chemical class 0.000 claims description 8
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical class C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical group COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- FVSUYFWWFUVGRG-UHFFFAOYSA-N naphthalen-1-ylurea Polymers C1=CC=C2C(NC(=O)N)=CC=CC2=C1 FVSUYFWWFUVGRG-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 abstract description 10
- 239000002464 receptor antagonist Substances 0.000 abstract description 5
- 229940044551 receptor antagonist Drugs 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000003828 downregulation Effects 0.000 abstract description 2
- 102100031168 CCN family member 2 Human genes 0.000 abstract 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 abstract 2
- 210000001508 eye Anatomy 0.000 description 31
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 27
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 17
- 210000001585 trabecular meshwork Anatomy 0.000 description 17
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 14
- 210000002744 extracellular matrix Anatomy 0.000 description 14
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 5
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FNBSOIBCKUUVJJ-LSLKUGRBSA-N 4-thiazolidinecarboxylic acid, 2-undecyl-, (4r)- Chemical compound CCCCCCCCCCCC1N[C@H](C(O)=O)CS1 FNBSOIBCKUUVJJ-LSLKUGRBSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 4
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 150000003409 sphingosine 1-phosphates Chemical class 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 102000007374 Smad Proteins Human genes 0.000 description 3
- 108010007945 Smad Proteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 3
- 201000006366 primary open angle glaucoma Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- -1 TGF-βR Proteins 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001384 anti-glaucoma Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 210000004786 perivascular cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000052185 transforming growth factor beta receptor activity proteins Human genes 0.000 description 2
- 108700015056 transforming growth factor beta receptor activity proteins Proteins 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
- 101100236683 Homo sapiens MBTPS1 gene Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102000049937 Smad4 Human genes 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- YZYDPPZYDIRSJT-UHFFFAOYSA-K boron phosphate Chemical compound [B+3].[O-]P([O-])([O-])=O YZYDPPZYDIRSJT-UHFFFAOYSA-K 0.000 description 1
- 229910000149 boron phosphate Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940042596 viscoat Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本出願は、米国特許法第119条の下、2006年7月25日に出願された米国仮特許出願第60/833,080号に基づく優先権を主張しており、その全体の内容は、本明細書中に参考として援用される。
本発明は、CTGF蓄積を含む目の障害における結合組織成長因子(CTGF)のレセプター信号伝達の下方制御および下流の低減された産生のための内皮分化遺伝子サブファミリー3レセプターの減衰のための組成物の分野に関する。
大部分の目の障害は、細胞増殖、生存、移動、分化、および血管新生を含む細胞プロセスと関連している。CTGFは、これら細胞プロセスにおける中心メディエーターであると考えられる分泌サイトカインである。特に、CTGFは、コラーゲンIおよびフィブロネクチンの増加した堆積により細胞外マトリックスを増加させることが知られている。CTGFの過剰発現は、細胞外マトリックス成分の過剰蓄積が存在する、強皮症、線維増殖性疾患、および瘢痕のような症状における主要な原因因子と関係している。
AC アデニルシクラーゼ
AP−1 アクチベータープロテイン1転写因子
CTGF 結合組織成長因子
DG ジアシルグリセロール
Edg3 内皮分化因子サブファミリー3レセプター、S1P3を参照のこと
ERK 細胞外−シグナル−調節キナーゼ
G12/13、Gq/11、Gi グアニンヌクレオチド−結合タンパク質のサブクラス
IOP 眼内圧
IP3 イノシトール三リン酸
LPA リソホスファチジン酸
PAI−1 プラスミノゲンアクチベーターインヒビター1
PKC プロテインキナーゼC
PLC ホスホリパーゼC
PLD ホスホリパーゼD
Raf プロテインキナーゼraf−1
Ras 小GTP−結合タンパク質
Rho 小GTP−結合タンパク質
S1P スフィンゴシン−1−ホスフェート
S1P3またはS1PR3 スフィンゴシン−1−ホスフェートレセプター3
Smad−1、−2、−3 レセプター調節Smad転写因子
Smad−4 共通パートナー(Co−)Smad転写因子
TGFβ トランスフォーミング成長因子β
TGFβR、TβRI、TβRII トランスフォーミング成長因子βレセプター、−I型レセプター、−II型レセプター
(発明の要旨)
本発明は、当該技術分野における上に記載される問題を取り扱い、そしてS1P−3レセプターのアンタゴニストを提供することによって、被験体の目におけるSmadシグナル伝達を減衰するための方法を提供する。被験体の目におけるSmadシグナル伝達を減衰する方法は、この被験体に、有効量の内皮分化遺伝子サブファミリー3レセプターのアンタゴニストまたはその薬学的に受容可能な塩、および薬学的に受容可能なキャリアを含む組成物を投与する工程を包含する。被験体の目におけるSmadシグナル伝達はそれによって減衰される。被験体は、Smadシグナル伝達に関連する目の障害を有し得、不適切な結合組織成長因子蓄積を生じるか、またはこのような目の障害を発症するリスクにあり得る。このSmadシグナル伝達に関連する目の障害は、例えば、高眼圧、緑内障、緑内障網膜症、眼神経症、黄斑変性、糖尿病性網膜症、脈絡膜新生血管、増殖性硝子体網膜症、および目創傷治癒であり得る。
S1P−3(Edg−3)レセプターは、LPAまたはS1Pのいずれかが内因性リガンドであるG−プロテイン連結レセプターのファミリーに属する。LPAは、Edg−2、−4、および−7レセプターに対するリガンドであり、そしてS1Pは、Edg−1、−3、−5、−6、および−8レセプターに対するリガンドである。これらEdgレセプターは、International Union of Pharmacology(Chunら、Pharmacol Rev、第54巻:265〜269、2002)によってS1Pレセプターに改名された。従って、本明細書で用いられるとき、用語「Edgレセプター」は、用語「S1Pレセプター」と同義語である。図1は、S1Pレセプターと調節標的Smadとの間の、そしてTGF−βレセプターと同じ調節標的Smadとの間のシグナル伝達関係の概略を提供する。Smadは、リン酸化反応によって活性化され、そしてSmad4との複合体は、核に侵入するヘテロマー複合体を生じ、そこで、この複合体は、その他の転写因子と一緒に、CTGFをコードする遺伝子の転写のような遺伝子転写を活性化する。
S1P−刺激性CTGF遺伝子発現の阻害
培養されたヒト小柱網細胞におけるCTGF遺伝子発現に対するEdg3レセプターの影響は、以下のように決定され得る。形質転換または非形質転換ヒトTM細胞培養(Pangら、Curr Eye Res、第13巻:51〜63、1994;Steelyら、Invest Ophthalmol Vis Sci、第33巻:2242〜2250、1992;Wilsonら、Curr Eye Res、第12巻:783〜793、1993;Stamerら、Curr Eye Res、第14巻:611〜617、1995)は、特定の期間、刺激量のスフィンゴシン−1−ホスフェート(S1P)を用いて、または用いないで、そしてEdg3レセプターアンタゴニスト用いて、または用いないで、処理される。別個の培養物がまた、コントロールとして供するために用いられた必要な希釈ビヒクルで処理される。総RNAが、次いで、TM細胞から、Qiagen RNeasy96を用い、製造業者(Qiagen)の指示書に従って単離される。
細胞外マトリックス関連タンパク質の発現におけるS1P−刺激性変化の阻害
培養されたヒト小柱網細胞における細胞外マトリックス関連タンパク質の発現に対するEdg3レセプターの影響は、以下のように決定され得る。ヒトTM細胞培養物は、複製群および/または実験群および/またはコントロール群に分割され、次いで、それらに希釈ビヒクル(コントロールとして)および/またはS1P(刺激作用因子として)および/またはEdg3レセプターアンタゴニストを含むコントロール溶液または実験溶液が添加される。フィブロネクチン、プラスミノゲンアクチベーターインヒビター(PAI−1)、コラーゲン、フィブリリン、ビトロネクチン、ラミニン、トロンポスポンジンI、プロテオグリカン、またはインテグリンのような細胞外マトリックス関連タンパク質のレベルが、次いで、標準的な酵素免疫測定法(ELISA)により各細胞培養群で測定される。このようなアッセイは、当業者に周知であり、そして特異的タンパク質の検出のためのマーカーとして抗体または抗原に結合した酵素を利用する高感度イムノアッセイである。これらの手段により、種々の細胞外マトリックス関連タンパク質のレベルが、次いで、実験溶液の効果を決定するために群間で比較され得る。
Claims (35)
- 被験体の目の中のSmadシグナル伝達を減衰する方法であって:
該被験体に、
有効量の内皮分化遺伝子サブファミリー3レセプターのアンタゴニストまたはその薬学的に受容可能な塩;および
薬学的に受容可能なキャリア
を含む組成物を含む組成物を投与する工程を包含し、それによって、該被験体の目の中のSmadシグナル伝達が減衰される、方法。 - 前記被験体が、不適切な結合組織成長因子蓄積をともなうSmadシグナル伝達に関連する目の障害を有する、請求項1に記載の方法。
- 前記被験体が、結合組織成長因子の不適切な蓄積をともなうSmadシグナル伝達に関連する目の障害を発症するリスクにある、請求項1に記載の方法。
- 前記Smadシグナル伝達に関連する目の障害が、高眼圧、緑内障、緑内障網膜症、眼神経症、黄斑変性、糖尿病性網膜症、脈絡膜新生血管、増殖性硝子体網膜症または目創傷治癒である、請求項2に記載の方法。
- 前記アンタゴニストが、スフィンゴシン−1−ホスフェートアナログである、請求項1に記載の方法。
- 前記アンタゴニストが、置換チアゾリジンである、請求項1に記載の方法。
- 前記アンタゴニストが、置換チアジナンである、請求項1に記載の方法。
- R1が、C10またはC11アルキルである、請求項8に記載の方法。
- R1が、アルキル置換フェニルであり、そして該置換がm−またはp−C7−アルキルである、請求項8に記載の方法。
- 前記アンタゴニストが、ポリスルホン化ナフチルウレアである、請求項1に記載の方法。
- 前記アンタゴニストが、前記レセプターに対する結合親和性および特異性を有する抗体またはその生物学的に活性なフラグメントである、請求項1に記載の方法。
- 前記アンタゴニストが、前記レセプターに対する結合親和性および特異性を有するペプチドまたは擬似ペプチドである、請求項1に記載の方法。
- 前記組成物が、局所投与、前房内投与、硝子体内投与、経強膜投与、またはインプラント経路を経由して、投与される、請求項1に記載の方法。
- 前記組成物中のアンタゴニストの濃度が、0.01%〜2%である、請求項1に記載の方法。
- 不適切な結合組織成長因子蓄積にともなうSmadシグナル伝達に関連する目の障害を処置する必要のある被験体において、該障害を処置する方法であって:
該被験体に、
有効量の内皮分化遺伝子サブファミリー3レセプターのアンタゴニストまたはその薬学的に受容可能な塩;および
薬学的に受容可能なキャリア
を含む組成物を投与する工程を包含し、それによって、該Smadシグナル伝達に関連する目の障害が処置される、方法。 - 前記被験体が、高眼圧または緑内障を有する、請求項18に記載の方法。
- 前記被験体が、高眼圧または緑内障を発症するリスクにある、請求項18に記載の方法。
- 前記アンタゴニストが、スフィンゴシン−1−ホスフェートアナログである、請求項18に記載の方法。
- 前記アンタゴニストが、置換チアゾリジンである、請求項18に記載の方法。
- 前記アンタゴニストが、置換チアジナンである、請求項18に記載の方法。
- R1が、C10またはC11アルキルである、請求項24に記載の方法。
- R1が、アルキル置換フェニルであり、そして該置換がm−またはp−C7−アルキルである、請求項24に記載の方法。
- 前記アンタゴニストが、ポリスルホン化ナフチルウレアである、請求項18に記載の方法。
- 前記アンタゴニストが、前記レセプターに対する結合親和性および特異性を有する抗体またはその生物学的に活性なフラグメントである、請求項18に記載の方法。
- 前記アンタゴニストが、前記レセプターに対する結合親和性および特異性を有するペプチドまたは擬似ペプチドである、請求項18に記載の方法。
- 前記組成物が、局所投与、前房内投与、硝子体内投与、経強膜投与、またはインプラント経路を経由して、投与される、請求項18に記載の方法。
- 前記組成物中のアンタゴニストの濃度が、0.01%〜2%である、請求項18に記載の方法。
- 被験体における緑内障を処置する方法であって:
該被験体に、
有効量の内皮分化遺伝子サブファミリー3レセプターのアンタゴニストまたはその薬学的に受容可能な塩;および
薬学的に受容可能なキャリア
を含む組成物を投与する工程を包含し、それによって、該緑内障が処置される、方法。 - 被験体における緑内障網膜症、眼神経症、黄斑変性、糖尿病性網膜症、脈絡膜新生血管、増殖性硝子体網膜症、または目創傷治癒を処置する方法であって:
該被験体に、
有効量の内皮分化遺伝子サブファミリー3レセプターのアンタゴニストまたはその薬学的に受容可能な塩;および
薬学的に受容可能なキャリア
を含む組成物を投与する工程を包含し、それによって、該緑内障網膜症、眼神経症、黄斑変性、糖尿病性網膜症、脈絡膜新生血管、増殖性硝子体網膜症、または目創傷治癒が処置される、方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83308006P | 2006-07-25 | 2006-07-25 | |
PCT/US2007/074351 WO2008014338A2 (en) | 2006-07-25 | 2007-07-25 | Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009544734A true JP2009544734A (ja) | 2009-12-17 |
JP2009544734A5 JP2009544734A5 (ja) | 2011-03-10 |
Family
ID=38982306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009521989A Pending JP2009544734A (ja) | 2006-07-25 | 2007-07-25 | 目の障害の予防および処置のための内皮分化遺伝子ファミリー3(edg−3、s1p3)レセプターのアンタゴニスト |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080025973A1 (ja) |
EP (1) | EP2068856A2 (ja) |
JP (1) | JP2009544734A (ja) |
KR (1) | KR20090033886A (ja) |
CN (1) | CN101505744A (ja) |
AU (1) | AU2007279311A1 (ja) |
BR (1) | BRPI0714593A2 (ja) |
CA (1) | CA2657480A1 (ja) |
MX (1) | MX2009000907A (ja) |
WO (1) | WO2008014338A2 (ja) |
ZA (1) | ZA200900316B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1772145B1 (en) | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
JP4792400B2 (ja) | 2004-10-12 | 2011-10-12 | 杏林製薬株式会社 | 2−アミノ−2−[2−[4−(3−ベンジルオキシフェニルチオ)−2−クロロフェニル]エチル]−1,3−プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体 |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
TWI396677B (zh) * | 2006-08-08 | 2013-05-21 | Kyorin Seiyaku Kk | An amine alcohol derivative and an immunosuppressive agent for use as an active ingredient |
US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
WO2009117335A2 (en) * | 2008-03-17 | 2009-09-24 | Allergan, Inc. | S1p3 receptor inhibitors for treating inflammation |
EP2427189A1 (en) * | 2009-05-05 | 2012-03-14 | Allergan, Inc. | S1p3 receptor inhibitors for treating conditions of the eye |
JP2013501794A (ja) * | 2009-08-11 | 2013-01-17 | アラーガン インコーポレイテッド | 目の疾患を治療するためのイソチオゾール |
US20130108557A1 (en) * | 2009-09-30 | 2013-05-02 | Albert Zorko Abram | Cosmetic foam |
CN102146411B (zh) * | 2011-01-06 | 2013-01-02 | 中国人民解放军第三军医大学第三附属医院 | 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019779A1 (en) * | 1994-01-21 | 1995-07-27 | Yale University | Deltex proteins, nucleic acids, and antibodies, and related methods and compositions |
JP2002332278A (ja) * | 2001-05-08 | 2002-11-22 | Human Science Shinko Zaidan | Edg受容体拮抗作用を有する複素環誘導体 |
JP2005247691A (ja) * | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013811A1 (de) * | 1993-11-17 | 1995-05-26 | Byk Nederland Bv | Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck |
US5545626A (en) * | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
AU2001236886A1 (en) * | 2000-02-09 | 2001-08-20 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
JP2001261575A (ja) * | 2000-03-13 | 2001-09-26 | General Hospital Corp | 血管収縮を調節する方法とその組成物 |
BR0309623A (pt) * | 2002-04-30 | 2005-02-09 | Alcon Inc | Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas |
EP1546110A4 (en) * | 2002-07-30 | 2008-03-26 | Univ Virginia | ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE |
US7109223B2 (en) * | 2002-08-28 | 2006-09-19 | Merck & Co. Inc. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma |
FR2845003A1 (fr) * | 2002-09-30 | 2004-04-02 | Merck Sante Sas | Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase |
AU2004259675A1 (en) * | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine CGRP receptor antagonists |
EP1827606A2 (en) * | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
US8546452B2 (en) * | 2005-10-12 | 2013-10-01 | Toa Eiyo Ltd. | S1P3 receptor antagonist |
CN101460458A (zh) * | 2006-02-15 | 2009-06-17 | 阿勒根公司 | 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物 |
-
2007
- 2007-07-25 EP EP07813352A patent/EP2068856A2/en not_active Withdrawn
- 2007-07-25 ZA ZA200900316A patent/ZA200900316B/xx unknown
- 2007-07-25 JP JP2009521989A patent/JP2009544734A/ja active Pending
- 2007-07-25 WO PCT/US2007/074351 patent/WO2008014338A2/en active Application Filing
- 2007-07-25 CN CNA2007800311386A patent/CN101505744A/zh active Pending
- 2007-07-25 US US11/828,137 patent/US20080025973A1/en not_active Abandoned
- 2007-07-25 MX MX2009000907A patent/MX2009000907A/es not_active Application Discontinuation
- 2007-07-25 KR KR1020097002077A patent/KR20090033886A/ko not_active Application Discontinuation
- 2007-07-25 AU AU2007279311A patent/AU2007279311A1/en not_active Abandoned
- 2007-07-25 BR BRPI0714593-4A patent/BRPI0714593A2/pt not_active IP Right Cessation
- 2007-07-25 CA CA002657480A patent/CA2657480A1/en not_active Abandoned
-
2010
- 2010-03-29 US US12/749,331 patent/US20100183629A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019779A1 (en) * | 1994-01-21 | 1995-07-27 | Yale University | Deltex proteins, nucleic acids, and antibodies, and related methods and compositions |
JP2002332278A (ja) * | 2001-05-08 | 2002-11-22 | Human Science Shinko Zaidan | Edg受容体拮抗作用を有する複素環誘導体 |
JP2005247691A (ja) * | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0714593A2 (pt) | 2013-05-07 |
WO2008014338A2 (en) | 2008-01-31 |
ZA200900316B (en) | 2010-05-26 |
US20080025973A1 (en) | 2008-01-31 |
KR20090033886A (ko) | 2009-04-06 |
AU2007279311A1 (en) | 2008-01-31 |
CN101505744A (zh) | 2009-08-12 |
CA2657480A1 (en) | 2008-01-31 |
US20100183629A1 (en) | 2010-07-22 |
EP2068856A2 (en) | 2009-06-17 |
MX2009000907A (es) | 2009-02-04 |
WO2008014338A3 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009544734A (ja) | 目の障害の予防および処置のための内皮分化遺伝子ファミリー3(edg−3、s1p3)レセプターのアンタゴニスト | |
Tanna et al. | Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension | |
EP2262476B1 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
US20120115870A1 (en) | Control of intraocular pressure using alk5 modulation agents | |
WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
RU2370267C2 (ru) | Антагонисты cdk2 в качестве антагонистов короткой формы фактора транскрипции c-maf для лечения глаукомы | |
JP2011521969A (ja) | 眼疾患を治療するためのTGF−β受容体阻害剤又はアクチビン様キナーゼ(ALK)5阻害剤、A−83−01及びSB−431542の使用方法及び創傷治療条件 | |
AU2011282681B2 (en) | Preservative free bimatoprost and timolol solutions | |
JP4482726B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
US20210113529A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
US20110105574A1 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
US20100247548A1 (en) | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders | |
WO2022034909A1 (ja) | セペタプロストを含有する医薬製剤 | |
WO2014138018A1 (en) | Preservative free bimatoprost and timolol solutions | |
Mokbel et al. | Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature | |
US20210363247A1 (en) | Novel Treatments of Glaucoma | |
TW201927298A (zh) | 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥 | |
Toris et al. | Aqueous humor dynamics II: clinical studies | |
EP3668487A1 (en) | Modulation of wnt5a to treat glaucoma | |
JP7429500B2 (ja) | 角膜上皮障害治療剤 | |
WO2004047868A1 (ja) | Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 | |
KR20080111092A (ko) | 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제 | |
Virani et al. | An Update on Pharmacotherapy of Glaucoma | |
US20100158897A1 (en) | Pai-1 modulators for the treatment of ocular disorders | |
JP2004189735A (ja) | Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120723 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120730 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120830 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120830 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121129 |